NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $13.66 -1.20 (-8.08%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$14.27 +0.61 (+4.47%) As of 11/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About SELLAS Life Sciences Group Stock (NASDAQ:SLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SLS alerts:Sign Up Key Stats Today's Range$13.39▼$15.1950-Day Range$7.47▼$19.1552-Week Range$1.39▼$24.89Volume15.36 million shsAverage Volume7.65 million shsMarket Capitalization$2.78 billionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer. SELLAS has also been developing SLS009, a small-molecule CDK9 inhibitor being studied for blood cancers, including acute myeloid leukemia. SELLAS is headquartered in New York. Its chief executive officer is Angelos Stergiou, who also serves as the company’s chairman.AI Generated. May Contain Errors. Read More SELLAS Life Sciences Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreSLS MarketRank™: 0.643165067445 of 5 starsSELLAS Life Sciences Group scored higher than 13% of companies evaluated by MarketBeat, and ranked 819th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Downside RiskSELLAS Life Sciences Group has a consensus price target of $10.00, representing about 26.8% downside from its current price of $13.66.Amount of Analyst CoverageSELLAS Life Sciences Group has only been the subject of 1 research reports in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -68.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -68.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSELLAS Life Sciences Group has a P/B Ratio of 21.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.66% of the float of SELLAS Life Sciences Group has been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 6.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.29 News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 54 news articles for SELLAS Life Sciences Group this week, compared to 5 articles on an average week.Search Interest36 people have searched for SLS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows14 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $206,454.00 in company stock.Percentage Held by Insiders1.30% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by Institutions17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLS Stock News HeadlinesSELLAS Life Sciences Group (NASDAQ:SLS) Stock: Insider John Thomas Burns Sells 3,831 SharesNovember 21 at 7:52 AM | insidertrades.comSELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNovember 20 at 8:36 PM | markets.businessinsider.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 21 at 1:00 AM | Base Camp Trading (Ad)SELLAS Life Sciences Group Closes $172.5 Million Public Offering of Common StockNovember 20 at 4:31 PM | quiverquant.comQSELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNovember 20 at 4:01 PM | globenewswire.comSellas Life Sciences Scores A Big Win: Here's What We Know (And What We Don't) (Rating Upgrade)November 20 at 9:14 AM | seekingalpha.comSLS stock suffers worst rout since January after $150M share sale — but fresh filing has retail bulls saying Sellas has more buyout leverageNovember 20 at 4:13 AM | msn.comSellas Life Sciences Shares Sink After Pricing Public OfferingNovember 19 at 7:49 AM | marketwatch.comSee More Headlines SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $3.77 at the beginning of 2026. Since then, SLS shares have increased by 262.3% and is now trading at $13.66. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its earnings results on Thursday, November, 12th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group's stock reverse split on the morning of Friday, November 8th 2019.The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are SELLAS Life Sciences Group's major shareholders? SELLAS Life Sciences Group's top institutional investors include State Street Corp (5.14%), Dagco Inc. (0.66%), Goldman Sachs Group Inc. (0.54%) and Marshall Wace LLP (0.14%). Insiders that own company stock include John Thomas Burns, Dragan Cicic, Katherine Bach Kalin, Jane Wasman and Nostrand Robert L Van. View institutional ownership trends. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SELLAS Life Sciences Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include NVIDIA (NVDA), Novavax (NVAX), Advanced Micro Devices (AMD), Ford Motor (F), Tesla (tsla), Inovio Pharmaceuticals (INO) and Plug Power (PLUG). Company Calendar Last Earnings11/12/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, SLS's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SLS CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees13Year Founded2006Price Target and Rating Average Price Target for SELLAS Life Sciences Group$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside-26.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.95% Return on Assets-29.86% Debt Debt-to-Equity RatioN/A Current Ratio14.92 Quick Ratio14.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book21.02Miscellaneous Outstanding Shares203,860,000Free Float201,209,000Market Cap$2.78 billion OptionableOptionable Beta2.73 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:SLS) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSomething Strange Is Happening In MiamiOn December 14, President Trump will host leaders of the world's largest economies at his private Miami resort...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.